Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1672-1678

  Woo, Sukyung ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ALLOMETRY; ARTICLE; BODY WEIGHT; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; ERYTHROCYTE; HUMAN; LIFESPAN; MONKEY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; RAT STRAIN; RETICULOCYTE; SHEEP; SPECIES COMPARISON;

ANIMALS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; DOGS; ERYTHROPOIETIN, RECOMBINANT; HAPLORHINI; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTESTINAL ABSORPTION; NONLINEAR DYNAMICS; RABBITS; RATS; SHEEP; SPECIES SPECIFICITY;

MAMMALIA; RATTUS;

EID: 34548077901     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015248     Document Type: Article

References (40)

1. Allison AC (1960) Turnovers of erythrocytes and plasma proteins in mammals. Nature 188:37-40.
2. Bleuel H, Hoffmann R, Kaufmann B, Neubert P, Ochlich PP, and Schaumann W (1996) Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology 52:329-338.
3. Braeckman R (1999) Pharmacokinetics and pharmacodynamics of protein therapeutics, in Peptide and Protein Drug Analysis (Reid R ed) pp 633-669, University of British Columbia, Vancouver.
4. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, and Widness JA (2001) Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298:820-824.
5. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1:435-461.
6. Emmanouel DS, Goldwasser E, and Katz AI (1984) Metabolism of pure human erythropoietin in the rat. Am J Physiol 247:F168-F176.
7. Fu JS, Lertora JJ, Brookins J, Rice JC, and Fisher JW (1988) Pharmacokinetics of erythropoietin in intact and anephric dogs. J Lab Clin Med 111:669-676.
8. Gibaldi M and Perrier D (1982) Pharmacokinetics, Marcel Dekker, New York.
9. Grene-Lerouge NA, Bazin-Redureau MI, Debray M, and Scherrmann JM (1996) Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol 138:84-89.
10. Gronert GA, Fung DL, Jones JH, Shafer SL, Hildebrand SV, and Disbrow EA (1995) Allometry of pharmacokinetics and pharmacodynamics of the muscle relaxant metocurine in mammals. Am J Physiol 268:R85-R91.
11. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, and Abraham PA (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712.
12. Jensen JD, Jensen LW, and Madsen JK (1994) The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 46:333-337.
13. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, and Sugiyama Y (1997) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520-527.
14. Kato M, Okano K, Sakamoto Y, Miura K, Uchimura T, and Saito K (2001) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats. Arzneimittelforschung 51:91-95.
15. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, and Fox JA (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31-38.
16. Krzyzanski W, Ramakrishnan R, and Jusko WJ (1999) Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 27:467-489.
17. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, and Chou RC (1995) Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 84:1285-1290.
18. Lepist EI and Jusko WJ (2004) Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther 27:211-218.
19. Mager DE and Jusko WJ (2002) Receptor-mediated pharmacokinetic/ pharmacodynamic model of interferon-beta 1a in humans. Pharmacol Res 19:1537-1543.
20. Mahmood I (2000) Can absolute oral bioavailability in humans be predicted from animals? A comparison of allometry and different indirect methods. Drug Metab Drug Interact 16:143-155.
21. Mahmood I (2004) Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 93:177-185.
22. McLennan DN, Porter CJH, Edwards GA, Martin SW, Heatherington AC, and Charman SA (2005) Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther 313:345-351.
23. Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040.
24. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, and Green JD (1991) Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
25. Moritz KM, Lim GB, and Wintour EM (1997) Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 273:R1829-R1844.
26. Moriya H, Maitani Y, Shimoda N, Takayama K, and Nagai T (1997) Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharm Res 14:1621-1628.
27. Piroso E, Erslev AJ, Flaharty KK, and Caro J (1991) Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 36:105-110.
28. Porter CJ and Charman SA (2000) Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89:297-310.
29. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, and Jusko WJ (1998) Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 15:1895-1901.
30. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, and Jusko WJ (2003) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 306:324-331.
31. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, and Jusko WJ (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44:991-1002.
32. Richter WF, Gallati H, and Schiller C-D (1999) Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 27:21-25.
33. Supersaxo A, Hein WR, and Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167-169.
34. Sytkowski AJ (1980) Denaturation and renaturation of human erythropoietin. Biochem Biophys Res Commun 96:143-149.
35. Tang H and Mayersohn M (2006) A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 95:1783-1799.
36. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, and Lowe LS (1999) A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 20:217-223.
37. Wen D, Boissel JP, Tracy TE, Gruninger RH, Mulcahy LS, Czelusniak J, Goodman M, and Bunn HF (1993) Erythropoietin structure-function relationships: high degree of sequence homology among mammals. Blood 82:1507-1516.
38. Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, and Peters C (1996) In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 279:1205-1210.
39. Woo S, Krzyzanski W, and Jusko WJ (2006) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 319:1297-1306.
40. Yoon WH, Park SJ, Kim IC, and Lee MG (1997) Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 96:227-240.